Abstract
Quantifying multiple biomarkers with high sensitivity in tiny biological samples is essential to meet the growing demand for point-of-care testing. This paper reports the development of a novel microfluidic device integrated with mass-producible micropillar array electrodes (μAEs) for multiple biomarker detections. The μAE are mass-fabricated by soft lithography and hot embossing technique. Pt–Pd bimetallic nanoclusters (BNC) are modified on the surface of μAEs by constant potential (CP)/multi-potential step (MPS) electrodeposition strategies to improve the electroanalytical performance. The experimental result displays that Pt–Pd BNC/μAEs have good sensitivity enhancement compared with bare planar electrodes and bare μAEs, the enhancement being 56.5 and 9.5 times respectively, from the results of the H2O2 detection. Furthermore, glucose, uric acid and sarcosine were used as model biomarkers to show the biosensing capability with high sensitivity. The linear range and LOD of the glucose, uric acid and sarcosine detection are 0.1 mM–12 mM, 10 μM–800 μM and 2.5 μM–100 μM, 58.5, 3.4 and 0.4 μM, respectively. In particular, biosensing chips show wide linear ranges covering required detection ranges of glucose, uric acid and sarcosine in human serum, indicating the developed device has great potential in self-health management and clinical requirements.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
